Macrophage-associated markers of metaflammation are linked to metabolic dysfunction in pediatric obesity

Cytokine. 2023 Nov:171:156372. doi: 10.1016/j.cyto.2023.156372. Epub 2023 Sep 18.

Abstract

Backgpound: Metabolically driven chronic low-grade adipose tissue inflammation, so-called metaflammation, is a central feature in obesity. This inflammatory tone is largely driven by adipose tissue macrophages (ATM), which express pro- and anti-inflammatory markers and cytokines such as, e.g., IL-1 receptor antagonist (IL-1RA), CD163 and osteopontin (OPN). Metaflammation ultimately leads to the development of cardiometabolic diseases. This study aimed to evaluate the association between selected adipose tissue macrophage-associated markers and metabolic comorbidities in pediatric obesity.

Methods: From a pediatric cohort with obesity (n = 108), clinically thoroughly characterized including diverse routine blood parameters, oral glucose tolerance test and liver MRI, plasma IL-1RA, soluble (s)CD163 and OPN were measured by ELISA.

Results: We observed significantly higher IL-1RA, sCD163, and OPN levels in the plasma of children with metabolic-dysfunction associated fatty liver disease (MAFLD) and metabolic syndrome. Moreover, IL-1RA and sCD163 correlated with hepatic disease and apoptosis markers alanine aminotransferase and CK-18. IL-1RA concentrations additionally correlated with insulin resistance, while children with disturbed glucose metabolism had significantly higher levels of sCD163.

Conclusion: MAFLD and other metabolic disorders in pediatric patients with obesity are associated with an elevation of adipose tissue macrophage-related inflammation markers.

Keywords: Adipose tissue macrophages; Interleukin-1 receptor antagonist; Metabolic-dysfunction associated fatty liver disease; Osteopontin; Soluble CD163.

MeSH terms

  • Adipose Tissue / metabolism
  • Child
  • Humans
  • Inflammation / metabolism
  • Insulin Resistance*
  • Interleukin 1 Receptor Antagonist Protein / metabolism
  • Macrophages / metabolism
  • Non-alcoholic Fatty Liver Disease* / metabolism
  • Pediatric Obesity* / metabolism

Substances

  • Interleukin 1 Receptor Antagonist Protein